In the 2016 edition of Cohitec, a programme that allows and fosters the entry of entrepreneurs and Research and Development institutions into the market, Portuguese researchers participated in a project that aims to be a decision support tool, NeuroPsyCAD.

NeuroPsyCAD is a start-up created by Diana Prata along with Hugo Ferreira and Ricardo Maximiano.

The aim of NeuroPsyCAD is to fight Alzheimer's and Parkinson's diseases and to have a database of Alzheimer's cases and cases of mild cognitive deficits "which are symptomatically similar" but whose "evolution of the disease will be very different", thus requiring different treatments.

According to IMM Researcher Diana Prata, machine learning algorithms are trained to "look" at all the data all and find "a pattern that differentiates, for example, Alzheimer's from mild cognitive deficit".

NeuroPsyCAD is not expected to hit the market soon. At this moment, the goal is to test the solution, and doctors are asked to send the medical tests taken by patients to be analysed by this technology. After the analysis, NeuroPsyCAD sends a report with the findings. "We want to help when the patient goes to the doctor, the doctor sends us the scan and we give a report with an analysis based on these subtleties", says Diana Prata.

You can read the article here

Source: Jornal de Negócios
Image credits: Jornal de Negócios

Cristina Bastos
Editorial Team
news@medicina.ulisboa.pt